Arcutis Biotherapeutics, Inc. Stock Price, News & Analysis

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the grant of 21,000 restricted stock units to three new employees. The grants were approved by the company's Compensation Committee and issued under the 2022 Inducement Plan.

The stock units, granted on August 1, 2025, will vest over a four-year period, with 25% vesting annually on each anniversary of the vesting commencement date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Arcutis Biotherapeutics (Nasdaq: ARQT) reported strong Q2 2025 financial results, with net product revenue of $81.5 million, representing a 164% year-over-year increase and 28% sequential growth. The quarter was marked by significant achievements, including FDA approval of ZORYVE foam 0.3% for plaque psoriasis treatment and the initiation of the INTEGUMENT-INFANT study for ZORYVE cream in infants with atopic dermatitis.

Key financial metrics include reduced net loss of $15.9 million ($0.13 per share) compared to $52.3 million in Q2 2024, with cash reserves of $191.1 million. The company's ZORYVE portfolio showed strong performance across all formulations, with over 1 million total prescriptions dispensed to date. Additionally, Arcutis submitted an IND for ARQ-234, a novel fusion protein for atopic dermatitis treatment.

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has scheduled its second quarter 2025 financial results announcement for August 6, 2025 after market close.

The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast and presentation materials through the "Events" section of Arcutis' website, with an archived replay available afterward on their investor website.

Arcutis Biotherapeutics (Nasdaq: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology, has announced the granting of 14,000 restricted stock units to two new employees. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan, effective July 1, 2025.

The restricted stock units have a four-year vesting schedule, with 25% vesting annually, contingent on continuous employment. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced that its product ZORYVE® (roflumilast) cream 0.15% has received a strong recommendation in the American Academy of Dermatology's (AAD) updated guidelines for adult atopic dermatitis management. ZORYVE is the first FDA-approved branded topical PDE4 inhibitor for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis.

Among newly evaluated branded topical therapies, ZORYVE stands out as the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis. The recommendation highlights the drug's efficacy in improving pruritus and disease severity, favorable tolerability, and low discontinuation rates. The treatment targets a condition affecting over 16 million adults in the United States.

Arcutis Biotherapeutics (ARQT) has initiated a Phase 2 clinical trial for ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis. The INTEGUMENT-INFANT study will evaluate the safety and tolerability of the PDE4 inhibitor cream in children aged 3 months to less than 2 years over a four-week period. The trial addresses a significant unmet need, as atopic dermatitis affects 9.6 million children in the US, with up to 60% developing symptoms in their first year. ZORYVE, designed for once-daily topical application, represents a potential new treatment option in a market with limited approved therapies for infants.

Arcutis Biotherapeutics (NASDAQ: ARQT) has granted 72,000 restricted stock units (RSUs) to nine newly hired employees as part of their employment inducement package. The grants were approved by the company's Compensation Committee under the 2022 Inducement Plan, with a grant date of June 2, 2025. The RSUs will vest over a four-year period, with 25% vesting occurring on each annual anniversary of the vesting commencement date, contingent on continuous employment with Arcutis. This announcement is made in compliance with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics (ARQT) presented new long-term data for ZORYVE cream at the 2025 RAD Conference, showing significant efficacy in treating atopic dermatitis. The Phase 3 INTEGUMENT-OLE study demonstrated that children ages 2-5 who achieved disease clearance and switched to twice-weekly ZORYVE cream 0.05% maintained disease control for a median of 238 days. By week 52, 63.1% of participants aged 2-5 years and 55.7% of those 6 years and over achieved disease clearance or almost clear status. Notable improvements in itch reduction were observed, with about half of participants achieving no or minimal itch. The treatment showed strong safety profile with low treatment-related adverse events: 2.5% in ages 2-5 and 4.7% in ages 6 and over.

Arcutis Biotherapeutics (NASDAQ: ARQT), a commercial-stage biopharmaceutical company specializing in immuno-dermatology innovations, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on Tuesday, June 10, 2025, at 4:00 pm EDT. The event will be accessible via webcast in the "Events" section of Arcutis' website, with the replay remaining available for 180 days after the conference.